S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom

Leap Therapeutics (LPTX) Earnings Date, Estimates & Call Transcripts

$3.00
+0.02 (+0.67%)
(As of 04/17/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 20Estimated
Actual EPS
(Mar. 18)
-$0.46 Beat By $0.10
Consensus EPS
(Mar. 18)
-$0.56
Skip Charts & View Estimated and Actual Earnings Data

LPTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LPTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Leap Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.58)($0.58)($0.58)
Q2 20241($0.59)($0.59)($0.59)
Q3 20241($0.59)($0.59)($0.59)
Q4 20241($0.60)($0.60)($0.60)
FY 20244($2.36)($2.36)($2.36)
Q1 20251($0.13)($0.13)($0.13)
Q2 20251($0.05)($0.05)($0.05)
Q3 20251$0.01$0.01$0.01
Q4 20251$0.07$0.07$0.07
FY 20254($0.10)($0.10)($0.10)

LPTX Earnings Date and Information

Leap Therapeutics last released its quarterly earnings data on March 18th, 2024. The reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10. Leap Therapeutics has generated ($5.08) earnings per share over the last year (($5.08) diluted earnings per share). Earnings for Leap Therapeutics are expected to grow in the coming year, from ($2.08) to ($1.15) per share. Leap Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off prior year's report dates.

Leap Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/20/2024
Estimated)
------- 
3/18/2024Q4 2023($0.56)($0.46)+$0.10($0.46)--
11/13/2023Q3 2023($0.58)($0.51)+$0.07($0.51)--
8/14/2023Q2 2023($0.90)($0.91)($0.01)($0.91)--
5/15/2023Q1 2023($0.90)($3.20)($2.30)($0.32)--
3/24/2023Q4 2022($0.90)($1.10)($0.20)($0.11)--
11/14/2022Q3 2022($1.10)($1.30)($0.20)($0.13)--
8/12/2022Q2 2022($1.00)($1.50)($0.50)($0.15)--
5/13/2022Q1 2022($1.10)($0.90)+$0.20($0.09)--
3/11/2022Q4 2021($1.10)($1.00)+$0.10($0.10)$0.38 million$0.38 million
11/12/2021Q3 2021($1.10)($1.40)($0.30)($0.14)$0.38 million$0.38 million
8/12/2021Q2 2021($1.20)($1.20)-($0.12)$0.38 million$0.38 million
5/14/2021Q1 2021($1.10)($1.20)($0.10)($0.12)$0.39 million$0.38 million

Leap Therapeutics Earnings - Frequently Asked Questions

When is Leap Therapeutics's earnings date?

Leap Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off last year's report dates. Learn more on LPTX's earnings history.

Did Leap Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Leap Therapeutics (NASDAQ:LPTX) reported ($0.46) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.56) by $0.10. Learn more on analysts' earnings estimate vs. LPTX's actual earnings.

How much revenue does Leap Therapeutics generate each year?

Leap Therapeutics (NASDAQ:LPTX) has a recorded annual revenue of $1.50 million.

How much profit does Leap Therapeutics generate each year?

Leap Therapeutics (NASDAQ:LPTX) has a recorded net income of -$81.41 million. LPTX has generated -$5.08 earnings per share over the last four quarters.

What is Leap Therapeutics's EPS forecast for next year?

Leap Therapeutics's earnings are expected to grow from ($2.08) per share to ($1.15) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:LPTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners